ESC 365 - Antifibrotic and anti-inflammatory effects of the selective nonsteroidal MR antagonist finerenone in preclinical pulmonary fibrosis

ESC Premium Access

Antifibrotic and anti-inflammatory effects of the selective nonsteroidal MR antagonist finerenone in preclinical pulmonary fibrosis

Session: Congress committee e-posters choice in pharmacology and pharmacotherapy

Topic: Aldosterone Antagonists

Speaker: Doctor M. Delbeck (Wuppertal, DE)

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

About the speaker

Doctor Martina Delbeck

Wuppertal (Germany)

0 follower

17 more presentations in this session

Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients with atrial fibrillation on direct-acting oral anticoagulants

Speaker: Mr A. Holt (Copenhagen, DK)

Usage and risk with phosphodiesterase type 5 inhibitors in male patients with chronic ischemic heart disease on oral organic nitrates

Speaker: Mr A. Holt (Copenhagen, DK)

PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual kinetic mechanism of action

Speaker: Mr Q. Ying (Perth, AU)

Aspirin vs. P2Y12 inhibitors with anticoagulation therapy for atrial fibrillation: insights from the AFIRE trial

Speaker: Assistant Professor H. Fukaya (Sagamihara, JP)

Renal decline in patients with atrial fibrillation treated with rivaroxaban or warfarin: a population-based cohort study in the United Kingdom

Speaker: Doctor Y. Lenz (Berlin, DE)

Access the full session

Congress committee e-posters choice in pharmacology and pharmacotherapy

Speakers: Doctor M. Delbeck, Mr A. Holt, Mr A. Holt, Mr Q. Ying, Assistant Professor H. Fukaya...

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

Related content

ESC Premium Access

Endotrophin is significantly associated with disease severity and increased risk of adverse outcome in HFpEF but not in HFrEF patients

27 August 2021

ESC Premium Access

Urate lowering therapy is associated with a lower risk of heart failure hospitalisation or mortality in hyperuricaemic patients with heart failure: a comparative effectiveness study

27 August 2021

ESC Premium Access

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

27 August 2021

ESC 365 is supported by